BAM
LKFT

Blueshift Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Blueshift Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,199
Closed -$248K – 392
2019
Q4 		$248K Buy
+1,199
New +$222K 0.03% 662

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Blueshift Asset Management's LKFT Position: Q1 2020 in Review

Blueshift Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q1 2020, closing a stake of 1,199 shares — an estimated $248K sold.

Blueshift Asset Management first reported a position in LKFT in Q4 2019 and held it in 1 quarter. The position peaked at $248K in Q4 2019. 141 funds tracked by Wall St. Rank hold LKFT as of Q1 2020.

  • Blueshift Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q1 2020 after selling out during the quarter.
  • Blueshift Asset Management sold 1,199 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2020, an estimated $248K.
  • Blueshift Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and held it in 1 quarter.
  • Blueshift Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $248K in Q4 2019.
  • 141 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2020.

Based on Blueshift Asset Management's 13F filing for Q1 2020, filed 14 May 2020.